Hjem › Ikke-småcellet lungekreft › Nevada
Kliniske studier for Ikke-småcellet lungekreft i Nevada
25 studier for Ikke-småcellet lungekreft søker deltakere på steder i Nevada.
Byer i Nevada
Offisiell studietekst (engelsk)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04267848Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #55, Las Vegas
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05176483A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207), Reno
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07513376A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Renown Health Medical Oncology, Reno
- Renown Office of Clinical Research, Reno
- Renown Regional Medical Center, Reno
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07144280A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0037), Reno
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06312137Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134), Reno
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06170788A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Reno
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06868277A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Renown Regional Medical Center, Reno
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT06561386Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT06357533A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Renown Regional Medical Center /ID# 273535, Reno
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06568939Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Renown Regional Medical Center, Reno
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07100080Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Cancer Care Specialists, Reno
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07195695Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- OptumCare Nevada, Las Vegas
- Local Institution - 007-938A, Las Vegas
- Local Institution - 007-938B, Las Vegas
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT04613596Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Renown Regional Medical Center, Reno
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06899126A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Cancer Care Specialists, Reno
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07541170A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Cancer Care Specialists, Reno
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Comprehensive Cancer Centers of Nevada, Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06119581Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Research Site, Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 26. aug. 2026 · NCT06350097A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT04389632Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. jun. 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
RekruttererFase 2
18 Minutes · Alle kjønn · Oppdatert 5. mai 2026 · NCT06031688Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- OptumCare Cancer Care at Seven Hills, Henderson
- OptumCare Cancer Care at Charleston, Las Vegas
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06418204GEMINI-NSCLC: NSCLC Biomarker Study
- OptumCare Cancer Care, Las Vegas
- Hope Cancer Care of Nevada, Las Vegas
- Cancer Care Specialists Reno, Reno
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 5. feb. 2026 · NCT05236114A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 110, Las Vegas
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 21. nov. 2025 · NCT05914116Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.